Glycemia-lowering effect of cobalt chloride in the diabetic rat: role of decreased gluconeogenesis.
Results of previous studies indicated that treatment of diabetic rats (induced by streptozotocin) with cobalt chloride (CoCl2) resulted in a significant decrement in serum glucose concentration. The present study was designed to determine the potential role of enhanced glucose uptake vs. decreased glucose production in the above response. The rate of systemic appearance of glucose, measured under fasting conditions using [3-3H]glucose tracer, was reduced from 35.5 +/- 2.5 to 17.5 +/- 1.8 micromol . kg-1 . min-1 in diabetic rats treated with 2 mM CoCl2 added to the drinking water for 10-14 days (P < 0.01). Tissue accumulation of intravenously administered 2-deoxy-[14C]glucose was significantly reduced in kidney and eye of diabetic rats treated with CoCl2, whereas the uptake remained unchanged in several other tissues including cerebrum, red and white skeletal muscle, heart, and liver. The relative content of phosphoenolpyruvate carboxykinase (PEPCK) mRNA was increased 3.1-fold in livers of diabetic compared with normal rats (P < 0.001), and treatment of diabetic rats with CoCl2 decreased hepatic PEPCK mRNA levels to normal. The content of PEPCK mRNA in the liver was decreased by 33% in CoCl2-treated normal rats (P < 0.05). Treatment with CoCl2 resulted in no change in cAMP levels in the livers of either diabetic or normal rats. These results suggest that the glycemia-lowering effect of CoCl2 is mediated by reductions in the rate of systemic appearance of glucose and hepatic gluconeogenesis.
Saker
F
F
Department of Pediatrics, Case Western Reserve University, Cleveland, Ohio 44106-4951, USA.
Ybarra
J
J
Leahy
P
P
Hanson
R W
RW
Kalhan
S C
SC
Ismail-Beigi
F
F
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism*; D003035:Cobalt / Q000494:pharmacology* / Q000627:therapeutic use; D003847:Deoxyglucose / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000097:blood* / Q000188:drug therapy / Q000378:metabolism; D005123:Eye / Q000378:metabolism; D005215:Fasting; D005943:Gluconeogenesis / Q000187:drug effects*; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008297:Male; D010729:Phosphoenolpyruvate Carboxykinase (GTP) / Q000235:genetics; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D014316:Tritium
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D012333:RNA, Messenger; D014316:Tritium; D003035:Cobalt; D003847:Deoxyglucose; D010729:Phosphoenolpyruvate Carboxykinase (GTP); C018021:cobaltous chloride